PEG-b-PLL Nanoparticle Targeting CCK-B Receptors for siRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current chemotherapeutic agents for pancreatic ductal adenocarcinoma (PDAC) are not tumor-selective and fail to effectively target PDAC-specific mechanisms, while RNA interference therapies are prone to degradation in the bloodstream, making delivery challenging.
Innovation Solution
Development of a polyethylene glycol-block-poly(L-lysine) nanoparticle construct with a thiol-functionalized PEG and a cholecystokinin-B (CCK-B) receptor ligand, specifically targeting pancreatic cancer cells to deliver siRNA that downregulates gastrin and mutated KRAS, thereby inhibiting cancer growth and metastasis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapeutic agents are used, then they can be administered to treat pancreatic cancer, but they are not tumor-selective and fail to target PDAC-specific mechanisms
Solution Approach 1:
The delivery system is segmented into distinct functional modules: a targeting ligand (gastrin-10 peptide) that specifically binds to CCK-B receptors on PDAC cells, a polymer backbone (PEG-b-PLL) that provides structural integrity and siRNA complexation, and the therapeutic payload (siRNA). This segmentation allows each component to be optimized independently for its specific function while maintaining overall system effectiveness.
Solution Approach 2:
The PEG-b-PLL block copolymer acts as an intermediary carrier that bridges the gap between the hydrophilic targeting ligand and the hydrophobic siRNA payload. The polylysine block complexs with siRNA through electrostatic interactions, while the PEG block provides steric stabilization and enables conjugation of the gastrin-10 targeting peptide, facilitating targeted delivery to PDAC cells.
2Reliability
If RNA interference therapy is used, then it can target PDAC-specific mechanisms, but it is broken down in the bloodstream
Solution Approach 1:
The PEG-b-PLL block copolymer forms a protective shell around the siRNA payload through self-assembly. The hydrophilic PEG corona provides steric stabilization and protects the siRNA from nucleases in the bloodstream, while the cationic polylysine core complexs with siRNA. This protective shell structure enables siRNA to circulate in the bloodstream without degradation while maintaining its therapeutic integrity.
Solution Approach 2:
The delivery system employs a composite structure combining synthetic polymer (PEG-b-PLL) with biological therapeutic agent (siRNA). The polymer provides structural stability, protection from degradation, and targeting capability, while the siRNA provides the therapeutic mechanism. This composite approach synergistically combines the advantages of both materials to achieve stable bloodstream circulation and effective PDAC targeting.
3Reliability
If a targeted nanoparticle construct is developed, then it can deliver siRNA effectively to pancreatic cancer cells, but the construct complexity increases
Solution Approach 1:
The invention merges multiple critical functions into a single integrated nanoparticle construct: the PEG-b-PLL block copolymer simultaneously provides siRNA complexation capability, bloodstream stability through PEGylation, targeted delivery via conjugated gastrin-10 peptide, and cellular uptake facilitation. This consolidation of functions into one construct reduces the need for multiple separate components while achieving high delivery accuracy to PDAC cells.
Solution Approach 2:
The PEG-b-PLL block copolymer serves multiple functions within a single molecular architecture: the polylysine block complexs with siRNA, the PEG block provides steric stabilization and circulation half-life extension, and the conjugated gastrin-10 peptide enables specific targeting of CCK-B receptors on PDAC cells. This multi-functionality within a single polymer construct simplifies the overall delivery system while maintaining high delivery accuracy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted nanoparticle effectively delivers siRNA to pancreatic cancer cells, significantly reducing gastrin expression and inhibiting tumor growth and metastasis, demonstrating improved selectivity and stability compared to untargeted approaches.
Implementation Method 1
a siRNA complexed with the poly(L-lysine) of the polymer moiety
Implementation Method 2
a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety
Data Source
Figure 1~2
Figure 3
Figure 4A
AI summary
A construct, or a pharmaceutically acceptable salt thereof, comprising: (a) a polyethylene glycol-block-poly(L-lysine) polymer moiety, wherein the polyethylene glycol is thiol-functionalized; (b) a cholecystokinin-B (CCK-B) receptor ligand coupled to the polyethylene glycol of the polymer moiety; and (c) a siRNA complexed with the poly(L-lysine) of the polymer moiety, wherein the construct is neutralized.